閉経後のホルモン療法と脳卒中のリスク:心臓とエストロゲン・プロゲステン置換研究 (HERS)
J A Simon1, J Hsia, J A Cauley
1General Internal Medicine Section, Medical Service, Veterans Affairs Medical Center, San Francisco, CA 94121, USA. jasimon@itsa.ucsf.edu
Circulation
|February 7, 2001
まとめ
エストロゲンとプロゲステンの治療は,冠動脈疾患の閉経後の女性の脳卒中リスクを有意に変化させなかった. 主要な脳卒中予測要因には,年齢,高血圧,糖尿病,喫煙,心房細動が含まれる.
科学分野:
- 心血管医学 心血管医学
- エンドクリノロジー エンドクリノロジー
- 神経学 神経学とは
背景:
- 観察的研究は,ホルモン療法と脳卒中リスクに関する矛盾した結果をもたらしました.
- これまでの臨床試験では,この関連性を調べたことはありませんでした.
研究 の 目的:
- エストロゲン+プロゲステン療法と脳卒中リスクとの関係を調査する.
- ハート&エストロゲン・プロゲステン置換研究 (HERS) のデータを分析する.
主な方法:
- 2763人の閉経後の女性を対象としたランダム化比較試験.
- 結合エストロゲンとプロゲスティンの比較とプラセボ.
- 脳卒中の発生率と死亡率を評価するために,平均4.1年間の追跡調査を行った.
主要な成果:
- ホルモン療法は,非致死性脳卒中,致死性脳卒中,または一時的な性発作との有意な関連性を示さなかった.
- 独立した脳卒中予測要因が特定された:年齢増加,高血圧,糖尿病,喫煙,心房細動.
- 黒人女性の脳卒中リスクは高かったが,BMIは逆相関を示した.
結論:
- 結合された馬用エストロゲンとプロゲスタンの治療は,冠動脈疾患の閉経後の女性の脳卒中リスクに有意な影響を及ぼさなかった.
関連する概念動画
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Menopause
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...


